SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
| Autor: | Efi Skafida, Alexandros Briasoulis, Elena Kunadis, Michalis Liontos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou, Flora Zagouri, Maria Kaparelou, Angeliki Andrikopoulou, Ioannis P. Trougakos, Efstathios Kastritis, Konstantinos Koutsoukos, Evangelos Terpos, Ioanna Katsiana, Christos Markellos, Oraianthi Fiste |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty COVID-19 Vaccines Population Antineoplastic Agents Breast Neoplasms Antibodies Viral Article CDK4/6 inhibitors Breast cancer Immune system Immunity Internal medicine Pandemic medicine Humans education RC254-282 education.field_of_study biology SARS-CoV-2 business.industry Vaccination Cyclin-Dependent Kinase 4 COVID-19 Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cancer Cyclin-Dependent Kinase 6 General Medicine medicine.disease Antibodies Neutralizing biology.protein Female Surgery Antibody business |
| Zdroj: | Breast, Vol 60, Iss, Pp 58-61 (2021) The Breast : Official Journal of the European Society of Mastology |
| ISSN: | 0960-9776 |
| DOI: | 10.1016/j.breast.2021.08.017 |
| Popis: | Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect